Overview of the treatment of myelodysplastic syndromes - UpToDate

uptodate.com · 420 words · saved by 1 readers

INTRODUCTION Myelodysplastic syndromes (MDS) comprise a group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia), and abnormal cellular maturation. Patients are at risk for symptoms related to anemia, infection, and bleeding, and they have variable rates of transformation to acute myeloid leukemia (AML). (See "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)".) This topic will provide an overview of the treatment of MDS. Detailed discussions of the following issues are presented separately: ● (See "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)".) ● (See "Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults".) ● (See "Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS".) ● (See "Treatment of lower-risk myelodysplastic syndromes (MDS)".) ● (See "Treatment

Myelodysplastic syndromes/neoplasms (MDS): Overview of diagnosis and management INTRODUCTION Myelodysplastic syndromes/neoplasms (MDS) comprise a diverse group of clonal hematologic malignancies that manifest as one or more cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia) typically accompanied by morphologic changes in bone marrow and blood cells. The genetic variants leading to the diseases are predominantly acquired, though occasionally MDS can be caused by germline predisposition. Most patients with MDS experience symptoms related to anemia, bleeding, and/or infection, but…

Overview of the treatment of myelodysplastic syndromes - UpToDate

related reading